Sysmex (OTCMKTS:SSMXY) Issues Earnings Results, Beats Expectations By $0.01 EPS

Sysmex (OTCMKTS:SSMXY) announced its earnings results on Thursday. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01, reports. The business had revenue of $837.32 million during the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%.

Sysmex Stock Down 5.2%

Shares of OTCMKTS SSMXY traded down $0.52 during trading hours on Thursday, hitting $9.48. 48,014 shares of the stock were exchanged, compared to its average volume of 272,492. Sysmex has a 12 month low of $9.00 and a 12 month high of $19.85. The firm has a fifty day moving average price of $9.74 and a 200-day moving average price of $11.40. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The company has a market cap of $5.97 billion, a PE ratio of 18.96 and a beta of 1.14.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.